Novartis AG (VTX:NOVN) has been given a CHF 90 price objective by equities research analysts at HSBC Holdings plc in a research report issued to clients and investors on Thursday. The firm presently has a “buy” rating on the stock.

Other equities analysts have also issued research reports about the stock. Berenberg Bank set a CHF 85 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, July 14th. J P Morgan Chase & Co set a CHF 75 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Wednesday, July 19th. Deutsche Bank AG set a CHF 81 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, July 14th. Finally, Barclays PLC set a CHF 80 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, June 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of CHF 85.17.

Shares of Novartis AG (VTX NOVN) opened at 84.10 on Thursday. The stock has a market cap of CHK 197.04 billion and a price-to-earnings ratio of 30.70. The company has a 50-day moving average price of CHK 82.04 and a 200-day moving average price of CHK 79.51. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.60.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/12/novartis-ag-novn-given-a-chf-90-price-target-at-hsbc-holdings-plc.html.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.